Genetic Predisposition Validated in Medulloblastoma
By LabMedica International staff writers Posted on 22 May 2018 |
Image: Six genes have been identified that predispose carriers to develop the brain tumor medulloblastoma (Photo courtesy of St. Jude Children\'s Research Hospital).
Medulloblastoma is a rare malignant tumor of the brain and occurs predominantly in children and is associated with rare hereditary cancer predisposition syndromes. It is believed that in many cases hereditary gene defects trigger the development of this malignant disease.
The cause of medulloblastoma is largely unclear and most cases are presumed to arise sporadically. Medulloblastoma is an embryonal brain tumor of the cerebellum, with an annual age-adjusted incidence ranging from 2/1,000,000 cases to 5.8/1,000,000 cases worldwide.
A large team of scientists led by those at the Heidelberg University Hospital (Heidelberg, Germany) analyzed patients with medulloblastoma from retrospective cohorts and from prospective cohorts from four clinical studies. These included a total of 1,022 patients with medulloblastoma, 673 from the retrospective cohorts and 349 from the four prospective studies from whom 1,022 blood samples and 800 tumor samples were analyzed for germline mutations in 110 cancer predisposition genes.
The scientists generated whole-genome and whole-exome sequencing data for germline and tumor samples at different institutes. To ensure standardization of genomic data processing, they used the same uniform computational analysis workflows for all germline and tumor samples. DNA methylation profiling was implemented to determine consensus molecular subgroups. The scientists were able to characterize medulloblastoma more accurately and to derive recommendations for genetic testing based on analysis of the patients with medulloblastoma.
Along with APC, BRCA2 and TP53, the other predisposition genes identified in the study were PALB2, PTCH1 and SUFU. The gene variations are predicted to change the encoded protein and disrupt the genes' normal function. Considering the six significantly enriched genes, about 5% of patients had an increased risk of cancer. Taking into account all cancer risk genes, about 11% of the patients had an increased cancer risk. Looking at a particular tumor subgroup, the so called "Sonic Hedgehog (SHH)-activated medulloblastoma", even 20% were identified to harbor a genetic predisposition to cancer.
Stefan M. Pfister, MD, a professor of Pediatric Neurooncology and senior author of the study said, “Hereditary disease factors usually have a significant impact on the whole family of the patient. We want to make genetic analysis available as a standard of care for patients with specific medulloblastoma.” The study was published on May 9, 2018, in the journal Lancet Oncology.
Related Links:
Heidelberg University Hospital
The cause of medulloblastoma is largely unclear and most cases are presumed to arise sporadically. Medulloblastoma is an embryonal brain tumor of the cerebellum, with an annual age-adjusted incidence ranging from 2/1,000,000 cases to 5.8/1,000,000 cases worldwide.
A large team of scientists led by those at the Heidelberg University Hospital (Heidelberg, Germany) analyzed patients with medulloblastoma from retrospective cohorts and from prospective cohorts from four clinical studies. These included a total of 1,022 patients with medulloblastoma, 673 from the retrospective cohorts and 349 from the four prospective studies from whom 1,022 blood samples and 800 tumor samples were analyzed for germline mutations in 110 cancer predisposition genes.
The scientists generated whole-genome and whole-exome sequencing data for germline and tumor samples at different institutes. To ensure standardization of genomic data processing, they used the same uniform computational analysis workflows for all germline and tumor samples. DNA methylation profiling was implemented to determine consensus molecular subgroups. The scientists were able to characterize medulloblastoma more accurately and to derive recommendations for genetic testing based on analysis of the patients with medulloblastoma.
Along with APC, BRCA2 and TP53, the other predisposition genes identified in the study were PALB2, PTCH1 and SUFU. The gene variations are predicted to change the encoded protein and disrupt the genes' normal function. Considering the six significantly enriched genes, about 5% of patients had an increased risk of cancer. Taking into account all cancer risk genes, about 11% of the patients had an increased cancer risk. Looking at a particular tumor subgroup, the so called "Sonic Hedgehog (SHH)-activated medulloblastoma", even 20% were identified to harbor a genetic predisposition to cancer.
Stefan M. Pfister, MD, a professor of Pediatric Neurooncology and senior author of the study said, “Hereditary disease factors usually have a significant impact on the whole family of the patient. We want to make genetic analysis available as a standard of care for patients with specific medulloblastoma.” The study was published on May 9, 2018, in the journal Lancet Oncology.
Related Links:
Heidelberg University Hospital
Latest Pathology News
- AI Integrated With Optical Imaging Technology Enables Rapid Intraoperative Diagnosis
- HPV Self-Collection Solution Improves Access to Cervical Cancer Testing
- Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
- AI Advancements Enable Leap into 3D Pathology
- New Blood Test Device Modeled on Leeches to Help Diagnose Malaria
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities